Yixintang Pharmaceutical Group Co., Ltd. (SHE:002727)
China · Delayed Price · Currency is CNY 11.57
+0.21 (1.85%)
May 29, 2026, 3:04 PM CST
SHE:002727 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | 279.17 | 263.43 | 114.14 | 549.44 | 1,010 | 921.58 |
Depreciation & Amortization | 1,239 | 1,239 | 1,258 | 1,158 | 1,001 | 1,088 |
Other Amortization | 186.05 | 186.05 | 183.18 | 175.95 | 153.66 | 129.41 |
Loss (Gain) From Sale of Assets | -8.79 | -8.79 | -3.18 | -1.12 | 0.28 | -0.06 |
Asset Writedown & Restructuring Costs | 24.73 | 24.73 | 28.94 | 14.59 | 26.14 | 13.68 |
Loss (Gain) From Sale of Investments | 7.1 | 7.1 | 3.43 | -0.56 | -1.77 | -8.5 |
Provision & Write-off of Bad Debts | 37.67 | 37.67 | 6.56 | 32.94 | 89.72 | 3.87 |
Other Operating Activities | 498.45 | 291.07 | 294.62 | 308.5 | 308.33 | 242.91 |
Change in Accounts Receivable | -23.4 | -23.4 | -43.99 | 407.33 | -765.83 | -739.71 |
Change in Inventory | 266.19 | 266.19 | -318.74 | -589.79 | -234.89 | -1,237 |
Change in Accounts Payable | -645.54 | -645.54 | 242.96 | 90.47 | 1,026 | 1,400 |
Change in Other Net Operating Assets | 4.74 | 4.74 | -40.64 | -35.69 | -80.17 | 4.92 |
Operating Cash Flow | 1,857 | 1,633 | 1,721 | 2,115 | 2,497 | 1,792 |
Operating Cash Flow Growth | 9.90% | -5.07% | -18.66% | -15.29% | 39.37% | 73.38% |
Capital Expenditures | -272.57 | -278.29 | -254.83 | -253.46 | -348.98 | -391.63 |
Sale of Property, Plant & Equipment | 0.83 | 0.34 | 0.34 | 23.19 | 3.68 | 4.39 |
Cash Acquisitions | -81.09 | -81.09 | -464.87 | -336.05 | -103.12 | -387.39 |
Divestitures | -1.7 | -1.7 | - | -0.29 | - | 1.01 |
Investment in Securities | 297.25 | 317.95 | -912.62 | -12.06 | 219.77 | 883.48 |
Other Investing Activities | 49.63 | 17.25 | 25.28 | 39.49 | 6.95 | 21.81 |
Investing Cash Flow | -7.66 | -25.54 | -1,607 | -539.19 | -221.71 | 131.67 |
Long-Term Debt Issued | - | 767.11 | 603.73 | 606.28 | 434 | 120 |
Total Debt Issued | 609.84 | 767.11 | 603.73 | 606.28 | 434 | 120 |
Long-Term Debt Repaid | - | -1,847 | -1,858 | -1,775 | -1,317 | -1,272 |
Total Debt Repaid | -1,864 | -1,847 | -1,858 | -1,775 | -1,317 | -1,272 |
Net Debt Issued (Repaid) | -1,254 | -1,080 | -1,255 | -1,169 | -882.72 | -1,152 |
Issuance of Common Stock | - | - | - | - | - | 16.75 |
Repurchase of Common Stock | -150 | -150 | -134.72 | -0.34 | -3.84 | -0.1 |
Common Dividends Paid | -304.04 | -304.89 | -260.54 | -260.44 | -191.64 | -180.91 |
Other Financing Activities | 195.51 | -6.27 | 2.94 | -19.62 | 0.01 | 11.29 |
Financing Cash Flow | -1,513 | -1,541 | -1,647 | -1,449 | -1,078 | -1,305 |
Foreign Exchange Rate Adjustments | - | - | - | 0.21 | 0.34 | -0.06 |
Net Cash Flow | 336.01 | 66.64 | -1,533 | 127.17 | 1,198 | 618.47 |
Free Cash Flow | 1,584 | 1,355 | 1,466 | 1,862 | 2,148 | 1,400 |
Free Cash Flow Growth | 13.45% | -7.55% | -21.28% | -13.33% | 53.43% | 85.89% |
Free Cash Flow Margin | 9.32% | 7.82% | 8.14% | 10.71% | 12.32% | 9.60% |
Free Cash Flow Per Share | 2.76 | 2.35 | 2.48 | 3.12 | 3.61 | 2.36 |
Cash Income Tax Paid | 512.32 | 510.61 | 844.59 | 538.36 | 410.13 | 407.48 |
Levered Free Cash Flow | 1,366 | 1,155 | 1,408 | 1,676 | 1,608 | 1,291 |
Unlevered Free Cash Flow | 1,446 | 1,238 | 1,499 | 1,760 | 1,667 | 1,376 |
Change in Working Capital | -406.6 | -406.6 | -165.31 | -122.33 | -89.89 | -598.98 |